Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Tibet Rhodiola Pharmaceutical Holding Co's Shareholder Yield % was 1.66%.
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Shareholder Yield % Explanation
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Tibet Rhodiola Pharmaceutical Holding Co Shareholder Yield % Related Terms
Tibet Rhodiola Pharmaceutical Holding Co Shareholder Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tibet Rhodiola Pharmaceutical Holding Co Shareholder Yield % Chart
Tibet Rhodiola Pharmaceutical Holding Co Annual Data
SHSE:600211 vs ZTS, UTHR: Shareholder Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Rhodiola Pharmaceutical Holding Co's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tibet Rhodiola Pharmaceutical Holding Co Shareholder Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tibet Rhodiola Pharmaceutical Holding Co's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Tibet Rhodiola Pharmaceutical Holding Co's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) has a Shareholder Yield % of 1.66% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors. This is 47% above median its historical median of 1.13. According to the industry distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #366 out of 973 companies in the Drug Manufacturers industry, placing it in the top 37.6%.
Is Tibet Rhodiola Pharmaceutical Holding Co's Shareholder Yield % too high?
Tibet Rhodiola Pharmaceutical Holding Co's current Shareholder Yield % of 1.66% is 47% above median its 10-year median of 1.13. The Drug Manufacturers industry median Shareholder Yield % is 0.31. Tibet Rhodiola Pharmaceutical Holding Co's value of 1.66% is 435.5% above this industry median. Based on the distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #366 out of 973 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Tibet Rhodiola Pharmaceutical Holding Co has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tibet Rhodiola Pharmaceutical Holding Co's Shareholder Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #366 out of 973 companies for Shareholder Yield %. This puts Tibet Rhodiola Pharmaceutical Holding Co in the upper half of its industry. The industry median Shareholder Yield % is 0.31. Tibet Rhodiola Pharmaceutical Holding Co's value of 1.66% is 435.5% above this benchmark. While the company's 10-year median is 1.13 vs. the industry median of 0.31, Tibet Rhodiola Pharmaceutical Holding Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Drug Manufacturers company?
The median Shareholder Yield % among Drug Manufacturers companies is 0.31, based on 973 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tibet Rhodiola Pharmaceutical Holding Co's current Shareholder Yield % of 1.66% is 435.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors. For the Drug Manufacturers industry, the median Shareholder Yield % is 0.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tibet Rhodiola Pharmaceutical Holding Co's current Shareholder Yield % is 1.66%, which is 47% above median its own 10-year median of 1.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tibet Rhodiola Pharmaceutical Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) is currently considered Fairly Valued. The stock's GF Value™ is ¥40.53, compared to a current price of ¥39.30 — trading 3% below its estimated fair value. The current Shareholder Yield % is 1.66%, which is 47% above median its 10-year median of 1.13 and 435.5% above the Drug Manufacturers industry median of 0.31. Tibet Rhodiola Pharmaceutical Holding Co's overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211), the current Shareholder Yield % is 1.66% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Overvalued in 2026?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co stock appears to be undervalued.
The current stock price of ¥39.30 is trading 3% below its estimated GF Value™ of ¥40.53.
GuruFocus considers Tibet Rhodiola Pharmaceutical Holding Co to be Fairly Valued.
Key valuation signals for SHSE:600211:
Shareholder Yield %: 1.66% (47% above median its 10-year median of 1.13)
GF Value™: ¥40.53 vs. price of ¥39.30 (3% below fair value)
Industry Position: 435.5% above the Drug Manufacturers median (#366 of 973)
No single metric tells the full story. See the SHSE:600211 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tibet Rhodiola Pharmaceutical Holding Co Business Description
Tibet Rhodiola Pharmaceutical Holding Co is a pharmaceutical company engaged in the production and sales of capsules, biological agents, granules, and coatings. The company's products cover biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical drugs, involving fields such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines.
94GF Score
Get the complete analysis for SHSE:600211
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600211 has been successfully added to your 
